Ones To Watch News
Refine Search
Biotechnology
Adding to several previous deals with the US pharma major, Dragonfly Therapeutics has now entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, including its extended half-life cytokine DF6002. 17 August 2020
Biotechnology
The US Food and Drug Administration has awarded Orphan Drug designation (ODD) and Rare Pediatric Disease designation (RPDD) to the drug candidate BBDF-101 for Batten disease, a rare, fatal, genetic disorder of the nervous system for which there is no treatment, under development by French CNS specialist Theranexus. 12 August 2020
Pharmaceutical
TerSera Therapeutics, a portfolio company of the Chicago, USA-based private equity firm GTCR, is to buy Xermelo (telotristat ethyl) from Lexicon Pharmaceuticals. 3 August 2020
Biotechnology
Dutch biotech firm Synaffix today announced that Swiss oncology-focused drug discovery firm ADC Therapeutics has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies. 23 July 2020
Biotechnology
Putting the final nail in the coffin for its non-alcoholic steatohepatitis (NASH) drug candidate, French metabolic specialist Genfit today announced the discontinuation of the RESOLVE-IT Phase III clinical trial of elafibranor in adults with NASH and fibrosis. 23 July 2020
Biotechnology
The USA’s Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of obeticholic acid (OCA), from Intercept Pharmaceuticals (Nasdaq: ICPT), for the treatment of non-alcoholic steatohepatitis (NASH) with fibrosis. 22 July 2020
Biotechnology
US precision cancer therapy specialist Blueprint Medicines has entered into a global collaboration with Swiss giant Roche and its subsidiary Genentech, worth a potential $1.7 billion. 14 July 2020
Pharmaceutical
Denmark-headquartered Abacus Medicine is set to acquire Dutch pharmaceutical wholesaler Pluripharm Group. 13 July 2020
Pharmaceutical
The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and affiliate ChemRar Group produced the first 100,000 courses of the Russian coronavirus drug Avifavir (favipiravir) in June, significantly exceeding initially planned production levels of 60,000 courses, the partners announced. 2 July 2020
Biotechnology
US clinical-stage immuno-oncology firm EpicentRx has entered into a licensing agreement for RRx-001, a small molecule immunotherapy targeting CD47 – SIRPα with ongoing Phase III trial in small cell lung cancer (SCLC), with China-owned SciClone Pharmaceuticals International. 1 July 2020
Biotechnology
In a therapy sector that has seen little success so far, Akero Therapeutics late yesterday announced results of a 16-week analysis of secondary and exploratory endpoints in its Phase IIa BALANCED study of efruxifermin (EFX), formerly known as AKR-001, in patients with non-alcoholic steatohepatitis (NASH). 1 July 2020
Biotechnology
Intercept Pharmaceuticals has received a complete response letter from the Food and Drug Administration regarding its New Drug Application (NDA) for obeticholic acid (OCA) for the treatment of fibrosis due to non-alcoholic steatohepatitis (NASH). 30 June 2020
Pharmaceutical
Tonix Pharmaceuticals and Southern Research have partnered to create a COVID-19 vaccine based on Tonix’ proprietary horsepox vaccine platform. 27 June 2020
Biotechnology
UK respiratory disease focussed biotech firm Synairgen has announced the expansion of the placebo-controlled home setting clinical trial of SNG001 (inhaled formulation of interferon-beta-1a) in patients with COVID-19. 18 June 2020
Biotechnology
A strategic licensing agreement has been reached between Stockholm’s Swedish Orphan Biovitrum and Massachusetts-based Selecta Biosciences. 12 June 2020
Biotechnology
Life sciences venture capital firm Forbion says that its newest portfolio company, Prilenia Therapeutics, a Naarden, Netherlands- and Herzliya, Israel-based clinical stage biotech company, has raised $62.5 million in a Series A financing round. 4 June 2020
Biotechnology
Novo Ventures, part of Denmark’s Novo Holdings, today announced that it has led the $55 million Series B financing in UK and USA-based biotech NodThera, which is developing a new class of medicines to treat diseases driven by chronic inflammation. Nanna Lüneborg, a partner at Novo Ventures, will join the NodThera board. 3 June 2020
Pharmaceutical
Canada-based precision oncology firm Repare Therapeutics has entered into an exclusive, worldwide, multi-target research collaboration with US pharma giant Bristol-Myers Squibb. 28 May 2020
Biotechnology
US biotech Humanigen has announced that the first COVID-19 patient has been dosed in its trial of lenzilumab, the company’s anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. 15 May 2020
Biotechnology
Cambridge, Massachusetts-based biotech Dyno Therapeutics has emerged from stealth with two strategic collaborations to develop improved gene therapies with AAV vectors based on AI (artificial intelligence) technology. 11 May 2020
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze